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Introduction
Thalassaemia is a hemoglobin disorder characterized
by the absence or reduced synthesis of globin chains,
a,~, y, 0, E and 1;: of human Hb. The two main types of
thalassaemia are a- and ~-thalassaemia.
Disorders of globin chain synthesis, including
thalassaemia, are common in Malaysia and constitute a
significant public health problem. There is no national
registry to determine the number of thalassaemia
patients, but the Health Ministry recently announced
that a census will be started to register all thalassaemia
patients and carriers in the country. Three to five
percent of Malaysians are estimated to be thalassaemia
carriers, which amounts to between 600,000 and one
million people!.
Alpha-thalassaemia is the most common hemoglobin
disorder in the world. Deletions of either one (a-
thalassaemia 2) or both. (a-thalassaemia 1) a-globin
genes on chromosome 16 account for over 95% of a-
thalassaemia cases'.
In Southeast Asia, the form of mutation in a-
thalassaemia 1 carriers is most commonly the SEA
deletion (__SEA). Couples who are carriers of a-
thalassaemia 1 are at risk of producing a Hb Bart's
hydrops fetalis offspring that usually dies in utero at the
third trimester of pregnancy or shortly after birth 2.
Phenotypically there are two forms of ~-thalassaemia:
~o _ no ~ globin chain synthesis, and W- with some ~
globin chain synthesis, clinically presenting as a trait (W
or W), thalassaemia intermedia (WIW or ~+I ~O) and ~­
thalassaemia major (WI W).
Beta-thalassaemia major patients are transfusion
dependent. Without transfusion, death occurs in the
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first few years of life. As a result· of repeated blood
transfusions iron overload will set in; desferrioxamine,
an iron-chelating agent, has to be given by continuous
infusion via pump afld is expensive. Without chelation,
they will die due to iron overload3. Cure being possible
in those who underwent an allogenic transplant with an
HLA matched donor with stem cells sourced from bone
marrow, peripheral blood or umbilical cord.
Classical f3-thalassaemia trait have hypochromic
microcytic, red cell indices, and a raised Hb Az with
values >4% when measured by high performance liquid
chromatography (HPLC)4. Red blood cells in a-
thalassaemia 1 are also hypochromic and microcytic,
and are presumptively identified by positive H
inclusion test and normal HbAz level. Confirmation of
a-thalassaemia 1 requires DNA studies.
Despite the same genotype, there is a remarkable
variability in severity of the clinical presentation of 13-
thalassaemia. Studies indicate that one of the genetic
factors that influence the severity of f3-thalassaemia is
the coinheritance of the a-thalassaemia gene.
Studies indicate that interactions between a- and 13-
thalassaemia must be considered when investigating
moderate to severe hypochromic microcytic anemia of
uncertain cause in adult patients from areas with a high
prevalence of globin gene mutations, and that the co-
inheritance of both a and f3-thalassaemia does indeed
occur in these areas, confirmed by PCR-based
techniques'·6.
Thus, the presence of f3-thalassaemia trait does not
exclude the simultaneous presence of a-thalassaemia 1.
Failure to detect both abnormalities may lead to a
failure to predict Hb Bart's hydrops fetalis when one
partner has a-thalassaemia 1 and the other has both a-
thalassaemia 1 and f3-thalassaemia trait? The laboratory
investigation of concurrent a-thalassaemia and 13-
thalassaemia is important for the identification of
people who are of reproductive age, and are potential
parents to offspring with Hb Bart's hydrops fetalis and
f3-thalassaemia major.
In view of the recent announcement of a national
screening program by the Ministry of Health, the result
of this study will indicate whether there is a need to
screen for a-thalassaemia 1 .in carriers with 13-




Two hundred and thirty one f3-thalassaemia samples
were studied. These cases were identified as classical
f3-thalassaemia carriers by low MCV<80fL, MCH<27pg
and a raised HbAz>4%. The numbers of samples
collected were appropriate statistically according to the
table given by World Health OrganizationS, with an
assumption that 10% of the f3-thalassaemia carriers
concurrently carry the a-thalassaemia 1 gene, according
to previous studies done in Hong Kong' and Guang-
Dong district in China9•
Approval for this study was obtained from the Medical
Ethics Committee at Faculty of Medicine and Health
Sciences, Universiti Putra Malaysia. The samples were
analyzed using conventional hematological methods.
For screening of thalassaemia and hemoglobinopathies,
the first step is a scrutiny of the red cell indices using a
cut-off value of MCV <80fL or an MCH <27pg7.
Automated blood counts and red blood cell indices
were generated on an automated blood counter
(Celldyne 1700, Abbott Laboratories, Abbott Park, IL,
USA).
The quantitation of Hb subtypes was by high
performance liquid chromatography (HPLC) (Variant,
Bio-Rad, Hercules, CA, USA). Accurate quantification
of HbAz for the diagnosis of a f3-thalassaemia trait is
imperative, and this is possible via that use of HPLC.
Raised HbAz of >4% is indicative of b-thalassaemia trait
when the Hb is quantified by HPLC4.
DNA was extracted from blood leucocytes using
commercial DNA extraction kits from Qiagen (Qiagen
Inc., Valencia, CA, USA). Gap-PCR was used
extensively for diagnosis of a-thalassaemia 1. This
method, based on methods by Winichagoon P. et aI,
1995 (10), was applied to detect the specific deletion of
20kb causing the molecular defect. The primers A4 (5'-
GGGGCGCCTTGGGGAGGTTC-3') and A9 (5'-
ATATATGGGTCTGGAAGTGTATC-3') are specific for a-
thaI (__SEA) deletion, and the primers A4 and AlB (5'-
GTTCCCTGAGCCCCGACACG-3') were used for normal
alleles.
In the gap-PCR reaction, the PCR product was
electrophorised on 1.5% agarose gel, stained with
ethidium bromide solution and studied on a UV
transilluminator. Separation based on fragment lengths
allowed the identification of the a-thalassaemia 1 gene.
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Results
Two hundred and thirty one b-thalassaemia samples
were studied. There were 118 Chinese (51.1%), 99
Malays (42.9%) and 14 of other races (6.1%) comprising
of five Orang Asli, three Thai, three Filipino, one
Indian, one Dusun and one of Indian and Thai mixed
heritage.
In the 231 [3-thalassaemia samples, 8 (3.5%) were found
to be concurrent carriers for a-thalassaemia 1. Six
C75.0%) were Chinese and 2 (25%) were Malays.
Discussion
Thalassaemias are common among Southeast Asians
and Southern Chinese. Due to the coexistence of
several thalassaemia and related genes in the same
area, Southeast Asia witnesses the most complex
thalassaemia syndromes unparalleled by other parts of
the world'.
The clinical presentations of a carrier with classical [3-
thalassaemia and a-thalassaemia 1 are very similar,
being asymptomatic, with both presenting with
microcytosis and hypochromia.
Thalassaemia screening begins with: scrutiny of full
blood count; measuring levels of different Hb subtypes
by HPLC; and measuring serum ferritin level to rule out
iron deficiency. Presumptive identification of a-
thalassaemia 1 is made when MCV<80fL, MCH<27pg,
HbAz<4.0%, serum ferritin level is normal, an H
inclusion test is positive and an increased ~-globin
chain level.
A positive H inclusion test and ~-globin assay might
indicate a-thalassaemia 1. The H inclusion test is
tedious and laborious. A negative result does not rule
out a-thalassaemia 1. The ~-globin assay by enzyme-
linked immunoabsorbent assay (ELISA) appears
promising as a screen testl1 ,12. Gap-PCR, a simple PCR
based DNA study accurately identifies a-thalassaemia 1
molecular defect.
Interactions of different mutations have been
reported5,6,13. In this study, the rate of co-inheritance of
a-thalassaemia 1 (__SEA) deletion among [3-thalassaemia
carriers was found to be 3.5%. This result indicates the
need to identify both a- and f3-thalassaemia genes so as
to prevent the birth of Hb Bart's hydrops fetalis and b-
thaI major.
Other studies reported the frequency of a-thalassaemia
1 (__SEA) deletion in f3-thalassaemia carriers as 9.1% (8 in
88) in Hong Kong (5) and 8.6% (43 in 500) in
GuangDong district, China9 . There have been no
published reports on the presence of concurrent
carriers for a- and [3-thalassaemia in Malaysia.
In year 2005, as Malaysia moves towards the
implementation of a national thalassaemia screening
program, it is important to include also the
identification of a-thalassaemia 1 in carriers of [3-
thalassaemia to prevent the births of Hb Bart's hydrops
fetalis.
The success in Sardinia, Italy and elsewhere in reducing
the prevalence of thalassaemia major by genetic
counseling shows that screening can have a major
impact in communities in which the thalassaemias are
common!4.!5.
Table I: Concurrent alpha thai 1 in beta-thalassaemia carriers
Race Samcles ADDroximate % Concurrent carriers % in resDective coculation
Malays 99 42.9 2 2.0
Chinese 118 51.1 6 5.1
Others 14 6.1 0 0
Total 231 100 8 3.5
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